Mural Oncology 2024 Investor Presentation

Mural Oncology plc presents its protein engineering capabilities and engineered cytokine programs, including nemvaleukin alfa for cancer immunotherapy. The presentation covers clinical development timelines, potential therapeutic applications across multiple tumor types, and combination therapy strategies within the ARTISTRY development program.